Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proposal of a study protocol of a preliminary double-blind randomized controlled trial. Verifying effects of selenium supplementation on selenoprotein p and s genes expression in protein and mRNA levels in subjects with coronary artery disease: selenegene.
Gharipour M, Sadeghi M, Behmanesh M, Salehi M, Roohafza H, Nezafati P, Khosravi E, Hosseini M, Keshvari M, Rouhi-Bourojeni H, Sarrafzadegan N. Gharipour M, et al. Among authors: salehi m. Acta Biomed. 2019 Jan 22;90(1):44-50. doi: 10.23750/abm.v90i1.6167. Acta Biomed. 2019. PMID: 30889154 Free PMC article.
Effects of selenium supplementation on expression of SEPP1 in mRNA and protein levels in subjects with and without metabolic syndrome suffering from coronary artery disease: Selenegene study a double-blind randomized controlled trial.
Gharipour M, Ouguerram K, Nazih EH, Salehi M, Behmanesh M, Roohafza H, Hosseini SM, Nezafati P, Dianatkhah M, Gharipour A, Haghjoo S, Sarrafzadegan N, Sadeghi M. Gharipour M, et al. Among authors: salehi m. J Cell Biochem. 2018 Nov;119(10):8282-8289. doi: 10.1002/jcb.26844. Epub 2018 Jun 22. J Cell Biochem. 2018. PMID: 29932230 Clinical Trial.
Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Lahmer T, Salmanton-García J, Marchesi F, El-Ashwah S, Nucci M, Besson C, Itri F, Jaksic O, Čolović N, Weinbergerová B, Seval GC, Adžić-Vukičević T, Szotkowski T, Sili U, Dargenio M, van Praet J, van Doesum J, Schönlein M, Ráčil Z, Žák P, Poulsen CB, Magliano G, Jiménez M, Bonuomo V, Piukovics K, Dragonetti G, Demirkan F, Blennow O, Valković T, Gomes Da Silva M, Maertens J, Glenthøj A, Fernández N, Bergantim R, Verga L, Petzer V, Omrani AS, Méndez GA, Machado M, Ledoux MP, Bailén R, Duarte RF, Del Principe MI, Farina F, Martín-Pérez S, Dávila-Valls J, Marchetti M, Bilgin YM, Fracchiolla NS, Cattaneo C, Espigado I, Cordoba R, Collins GP, Labrador J, Falces-Romero I, Prezioso L, Meers S, Passamonti F, Buquicchio C, López-García A, Kulasekararaj A, Ormazabal-Vélez I, Cuccaro A, Garcia-Vidal C, Busca A, Navrátil M, de Jonge N, Biernat MM, Guidetti A, Abu-Zeinah G, Samarkos M, Anastasopoulou A, de Ramón C, González-López TJ, Hoenigl M, Finizio O, Pinczés LI, Ali N, Vena A, Tascini C, Stojanoski Z, Merelli M, Emarah Z, Kohn M, Barać A, Mladenović M, Mišković B, Ilhan O, Çolak GM, Čerňan M, Gräfe SK, Ammatuna E, Hanakova M, Víšek B, Cabirta A, Nordlander A, Nunes Rodrigues R, Hersby DS, … See abstract for full author list ➔ Lahmer T, et al. Infection. 2024 May 21. doi: 10.1007/s15010-024-02240-x. Online ahead of print. Infection. 2024. PMID: 38771466 No abstract available.
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Salehi M, Alavi Darazam I, Nematollahi A, Alimohammadi M, Pouya S, Alimohammadi R, Khajavirad N, Porgoo M, Sedghi M, Mahdi Sepahi M, Azimi M, Hosseini H, Mahmoud Hashemi S, Dehghanizadeh S, Khoddami V. Salehi M, et al. Int Immunopharmacol. 2024 May 17;134:112192. doi: 10.1016/j.intimp.2024.112192. Online ahead of print. Int Immunopharmacol. 2024. PMID: 38761778
1,417 results